Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129872 | 0.92 | APLNR (0.56) | APLNRMAPTTP53CYP1A2CYP2C9 | |
| SCHEMBL1129497 | 0.87 | TP53 (0.68) | APLNRMAPTTP53CYP1A2CYP2C9 | |
| SCHEMBL1129075 | 0.83 | TP53 (0.64) | APLNRMAPTTP53MEN1KMT2A | |
| SCHEMBL1129573 | 0.80 | APLNR (0.61) | APLNRMAPTTP53CYP1A2CYP2C9 | |
| SCHEMBL1129052 | 0.80 | APLNR (0.61) | APLNRMAPTTP53CYP1A2CYP2C9 | |
| SCHEMBL1130423 | 0.80 | APLNR (0.61) | APLNRMAPTTP53CYP1A2CYP2C9 | |
| SCHEMBL1129305 | 0.79 | HPGD (0.50) | MAPTTP53MEN1KMT2AALDH1A1 | |
| SCHEMBL1129811 | 0.77 | APLNR (0.58) | APLNRMAPTTP53CYP1A2CYP2C9 | |
| SCHEMBL1129702 | 0.76 | TP53 (0.60) | APLNRMAPTTP53MEN1KMT2A | |
| SCHEMBL18923515 | 0.73 | PIK3CD (0.45) | APLNRMAPTTP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160231-A1 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | F2G LIMITED (GB) | 2011-06-30 | — | — | US | claimed |
| EP-2283151-A2 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | F2G Limited (GB) | 2011-02-16 | — | — | EP | claimed |
| WO-2009133379-A2 | ANTIFUNGAL TARGET | F2G LIMITED (GB) | 2009-11-05 | — | — | WO | claimed |
| EP-2283151-B1 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET | F2G LTD (GB) | 2017-03-08 | — | — | EP | disclosed |
| US-9034887-B2 | Dihydroorotate dehydrogenase as antifungal drug target and quinazolinone-based inhibitors thereof | F2G LIMITED (GB) | 2015-05-19 | — | — | US | disclosed |
| US-20110160231-A1 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | F2G LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| EP-2283151-A2 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | F2G Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009133379-A2 | ANTIFUNGAL TARGET | F2G LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160231-A1 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | DHODH, DHRS9, DLD | APLNR 4762/4885MAPT 3046/4885TP53 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.